European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - attention deficit disorder with hyperactivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv must be used as a part of a comprehensive adhd treatment programme, typically including psychological, educational and social measures.,

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - hydrocortisone - adrenal insufficiency - corticosteroids for systemic use - treatment of adrenal insufficiency in adults.

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride succinate - constipation - other drugs for constipation - resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin - diabetes mellitus, type 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 4.56 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 3.42 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 2.28 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 1.14 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - pantoprazole, quantity: 22.57 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: iron oxide yellow; povidone; polysorbate 80; crospovidone; purified water; hypromellose; titanium dioxide; sodium carbonate; sodium lauryl sulfate; triethyl citrate; propylene glycol; mannitol; methacrylic acid copolymer; calcium stearate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - somac heartburn relief is indicated for symptomatic relief of heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - vedolizumab, quantity: 331.2 mg - injection, powder for - excipient ingredients: polysorbate 80; arginine hydrochloride; histidine; sucrose; histidine hydrochloride monohydrate - ulcerative colitis,treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf-alpha) antagonist.,crohn?s disease,treatment of adult patients with moderate to severe crohn?s disease who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf-alpha) antagonist.,pouchitis,entyvio is indicated for the treatment of adult patients with moderate to severe chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.